PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia.


Journal

Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895

Informations de publication

Date de publication:
08 2019
Historique:
received: 06 09 2018
accepted: 04 02 2019
revised: 29 01 2019
pubmed: 8 3 2019
medline: 29 10 2019
entrez: 8 3 2019
Statut: ppublish

Résumé

Chromosomal rearrangements and specific aneuploidy patterns are initiating events and define subgroups in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Here we analyzed 250 BCP-ALL cases and identified a novel subgroup ('PAX5-plus', n = 19) by distinct DNA methylation and gene expression profiles. All patients in this subgroup harbored mutations in the B-lineage transcription factor PAX5, with p.P80R as hotspot. Mutations either affected two independent codons, consistent with compound heterozygosity, or suffered LOH predominantly through chromosome 9p aberrations. These biallelic events resulted in disruption of PAX5 transcriptional programs regulating B-cell differentiation and tumor suppressor functions. Homozygous CDKN2A/B deletions and RAS-activating hotspot mutations were highly enriched as cooperating events in the genomic profile of PAX5-plus ALL. Together, this defined a specific pattern of triple alterations, exclusive to the novel subgroup. PAX5-plus ALL was observed in pediatric and adult patients. Although restricted by the limited sample size, a tendency for more favorable clinical outcome was observed, with 10 of 12 adult PAX5-plus patients achieving long-term survival. PAX5-plus represents the first BCP-ALL subgroup defined by sequence alterations in contrast to gross chromosomal events and exemplifies how deregulated differentiation (PAX5), impaired cell cycle control (CDKN2A/B) and sustained proliferative signaling (RAS) cooperatively drive leukemogenesis.

Identifiants

pubmed: 30842609
doi: 10.1038/s41375-019-0430-z
pii: 10.1038/s41375-019-0430-z
doi:

Substances chimiques

Cyclin-Dependent Kinase Inhibitor p15 0
Cyclin-Dependent Kinase Inhibitor p16 0
PAX5 Transcription Factor 0
PAX5 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1895-1909

Auteurs

Lorenz Bastian (L)

Department of Hematology/Oncology, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.
Berlin Institute of Health, Berlin, Germany.
German Cancer Consortium (DKTK), Heidelberg, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Medicine II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany.

Michael P Schroeder (MP)

Department of Hematology/Oncology, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.

Cornelia Eckert (C)

German Cancer Consortium (DKTK), Heidelberg, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Pediatric Oncology/Hematology, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany.

Cornelia Schlee (C)

Department of Hematology/Oncology, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.

Jutta Ortiz Tanchez (JO)

Department of Hematology/Oncology, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.

Sebastian Kämpf (S)

Department of Hematology/Oncology, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.

Dimitrios L Wagner (DL)

Berlin Institute of Health, Berlin, Germany.
Institute for Medical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité - Universitätsmedizin Berlin, Berlin, Germany.

Veronika Schulze (V)

Department of Hematology/Oncology, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.

Konstandina Isaakidis (K)

Department of Hematology/Oncology, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.

Juan Lázaro-Navarro (J)

Department of Hematology/Oncology, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.
German Cancer Consortium (DKTK), Heidelberg, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.

Sonja Hänzelmann (S)

Department of Medicine II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany.

Alva Rani James (AR)

Department of Hematology/Oncology, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.
German Cancer Consortium (DKTK), Heidelberg, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.

Arif Ekici (A)

Institute of Human Genetics, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany.

Thomas Burmeister (T)

Department of Hematology/Oncology, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.

Stefan Schwartz (S)

Department of Hematology/Oncology, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.

Martin Schrappe (M)

University Hospital Schleswig-Holstein, Campus Kiel, Department of Pediatrics, Kiel, Germany.

Martin Horstmann (M)

Research Institute Children's Cancer Center, Dept. of Pediatric Hematology and Oncology, University Medical Center Hamburg, Hamburg, Germany.

Sebastian Vosberg (S)

German Cancer Consortium (DKTK), Heidelberg, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.

Stefan Krebs (S)

Laboratory for Functional Genome Analysis, Gene-Center, LMU Munich, Munich, Germany.

Helmut Blum (H)

Laboratory for Functional Genome Analysis, Gene-Center, LMU Munich, Munich, Germany.

Jochen Hecht (J)

Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.
Universitat Pompeu Fabra (UPF), Barcelona, Spain.

Philipp A Greif (PA)

German Cancer Consortium (DKTK), Heidelberg, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.

Michael A Rieger (MA)

German Cancer Consortium (DKTK), Heidelberg, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Medicine II, Hematology/Oncology, Goethe University Hospital, Frankfurt/M, Germany.

Monika Brüggemann (M)

Department of Medicine II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany.

Nicola Gökbuget (N)

German Cancer Consortium (DKTK), Heidelberg, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Medicine II, Hematology/Oncology, Goethe University Hospital, Frankfurt/M, Germany.

Martin Neumann (M)

Department of Hematology/Oncology, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.
German Cancer Consortium (DKTK), Heidelberg, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Medicine II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany.

Claudia D Baldus (CD)

Department of Hematology/Oncology, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany. claudia.baldus@uksh.de.
Berlin Institute of Health, Berlin, Germany. claudia.baldus@uksh.de.
German Cancer Consortium (DKTK), Heidelberg, Germany. claudia.baldus@uksh.de.
German Cancer Research Center (DKFZ), Heidelberg, Germany. claudia.baldus@uksh.de.
Department of Medicine II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany. claudia.baldus@uksh.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH